Skip to main content
SpringerLink
Log in

Overview of Animal Models

  • Chapter
  • First Online:
Scleroderma

  • 2146 Accesses

Abstract

The ability to sample fibrotic tissue in systemic sclerosis (SSc) by performing skin biopsy has been a major strength in trying to understand the pathobiology of this disease in comparison to other forms of organ-based fibrosis. It has permitted the identification of cardinal histological features of scleroderma and has defined key phases of the pathology in a temporal sequence so that there is now a clear understanding that as the disease develops, the first changes occur at the level of the dermal microcirculation followed by the development of inflammation that first involves cells of the innate immune and later adaptive immune system. Finally, there is the fibrotic stage of the disease that results in the replacement of specialized structures with rather vascular fibrotic connective tissue. The final component is the most important in determining the morbidity and mortality of SSc as it occurs in all target tissues. It is noteworthy that the activated pathways are largely overlapping with the biological responses during normal wound healing, but in contrast to physiological tissue responses to injury, they are not effectively terminated, but become chronically activated. In addition to defining these components of the SSc disease process, skin biopsy material has also proven valuable as a starting point to identify deregulated signaling cascades and to generate novel hypotheses. To test the importance of a candidate pathway, process, or mediator, it is necessary to explore the relevance experimentally. While experiments on cellular components isolated from affected tissues such as primary fibroblasts are essential to provide first proof of concept, there is a pressing need to further validate the results in vivo. Animal models of SSc are crucially required to close the gap between in vitro studies and clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 2010;62(10):2831–44.

    Article  CAS  PubMed  Google Scholar 

  2. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol. 1976;82(3):493–512.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res. 1996;6(4):300–13.

    Article  CAS  PubMed  Google Scholar 

  4. Kielty CM, Raghunath M, Siracusa LD, Sherratt MJ, Peters R, Shuttleworth CA, et al. The Tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J Cell Biol. 1998;140(5):1159–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lemaire R, Farina G, Kissin E, Shipley JM, Bona C, Korn JH, et al. Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum. 2004;50(3):915–26.

    Article  CAS  PubMed  Google Scholar 

  6. Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol. 2008;128(4):871–81.

    Article  CAS  PubMed  Google Scholar 

  7. Dees C, Akhmetshina A, Zerr P, Reich N, Palumbo K, Horn A, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2011;208(5):961–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor beta-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2012;64(5):1642–52.

    Article  CAS  PubMed  Google Scholar 

  9. Komura K, Fujimoto M, Yanaba K, Matsushita T, Matsushita Y, Horikawa M, et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis. 2008;67(6):867–72.

    Article  CAS  PubMed  Google Scholar 

  10. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002;109(11):1453–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Murai C, Saito S, Kasturi KN, Bona CA. Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. Autoimmunity. 1998;28(3):151–5.

    Article  CAS  PubMed  Google Scholar 

  12. Shibata S, Muryoi T, Saitoh Y, Brumeanu TD, Bona CA, Kasturi KN. Immunochemical and molecular characterization of anti-RNA polymerase I autoantibodies produced by tight skin mouse. J Clin Invest. 1993;92(2):984–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Walker MA, Harley RA, DeLustro FA, LeRoy EC. Adoptive transfer of tsk skin fibrosis to +/+ recipients by tsk bone marrow and spleen cells. Proc Soc Exp Biol Med Soc Exp Biol Med (New York, NY). 1989;192(2):196–200.

    Article  CAS  Google Scholar 

  14. Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun. 1993;6(6):701–18.

    Article  CAS  PubMed  Google Scholar 

  15. Siracusa LD, McGrath R, Fisher JK, Jimenez SA. The mouse tight skin (Tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mamm Genome: Off J Int Mamm Genome Soc. 1998;9(11):907–9.

    Article  CAS  Google Scholar 

  16. Kasturi KN, Hatakeyama A, Murai C, Gordon R, Phelps RG, Bona CA. B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. J Autoimmun. 1997;10(6):505–17.

    Article  CAS  PubMed  Google Scholar 

  17. Christner PJ, Peters J, Hawkins D, Siracusa LD, Jimenez SA. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum. 1995;38(12):1791–8.

    Article  CAS  PubMed  Google Scholar 

  18. Long KB, Li Z, Burgwin CM, Choe SG, Martyanov V, Sassi-Gaha S, et al. The Tsk2/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 gene. J Invest Dermatol. 2015;135(3):718–27.

    Article  CAS  PubMed  Google Scholar 

  19. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007;56(1):334–44.

    Article  CAS  PubMed  Google Scholar 

  20. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 2012;3:735.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Ann Rheum Dis. 2015;74(7):1408–16.

    Google Scholar 

  22. Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-beta signalling to prevent fibrosis. Ann Rheum Dis. 2014;73(6):1215–22.

    Article  CAS  PubMed  Google Scholar 

  23. Zerr P, Vollath S, Palumbo-Zerr K, Tomcik M, Huang J, Distler A, et al. Vitamin D receptor regulates TGF-beta signalling in systemic sclerosis. Ann Rheum Dis. 2015;74(3):e20.

    Google Scholar 

  24. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem. 2003;278(27):25109–19.

    Article  CAS  PubMed  Google Scholar 

  25. Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP. Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther. 2010;12(2):R69.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Derrett-Smith EC, Dooley A, Gilbane AJ, Trinder SL, Khan K, Baliga R, et al. Endothelial injury in a transforming growth factor beta-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum. 2013;65(11):2928–39.

    Article  CAS  PubMed  Google Scholar 

  27. Sonnylal S, Shi-Wen X, Leoni P, Naff K, Van Pelt CS, Nakamura H, et al. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 2010;62(5):1523–32.

    Article  PubMed  Google Scholar 

  28. Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, Lucas PC, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem. 2004;279(34):35503–9.

    Article  CAS  PubMed  Google Scholar 

  29. Wei J, Melichian D, Komura K, Hinchcliff M, Lam AP, Lafyatis R, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum. 2011;63(6):1707–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis. 2012;71(5):761–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Castello-Cros R, Whitaker-Menezes D, Molchansky A, Purkins G, Soslowsky LJ, Beason DP, et al. Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle (Georgetown, Tex). 2011;10(13):2140–50.

    Article  CAS  Google Scholar 

  32. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008;58(9):2854–65.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Le Saux O, Teeters K, Miyasato S, Choi J, Nakamatsu G, Richardson JA, et al. The role of caveolin-1 in pulmonary matrix remodeling and mechanical properties. Am J Physiol Lung Cell Mol Physiol. 2008;295(6):L1007–17.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008;294(5):L843–61.

    Article  CAS  PubMed  Google Scholar 

  35. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gooz P, et al. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010;69(6):1220–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203(13):2895–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yamaguchi Y, Yasuoka H, Stolz DB, Feghali-Bostwick CA. Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5. J Cell Mol Med. 2011;15(4):957–69.

    Article  CAS  PubMed  Google Scholar 

  38. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol. 2008;20(6):713–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A. 2002;99(6):3908–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005;52(3):856–64.

    Article  CAS  PubMed  Google Scholar 

  41. Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2008;14(4):365–78.

    Article  CAS  Google Scholar 

  42. Huu DL, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, et al. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum. 2013;65(6):1624–35.

    Article  CAS  PubMed  Google Scholar 

  43. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163(10):5693–9.

    CAS  PubMed  Google Scholar 

  44. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168(6):3088–98.

    Article  CAS  PubMed  Google Scholar 

  45. Zerr P, Distler A, Palumbo-Zerr K, Tomcik M, Vollath S, Dees C, et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol. 2012;181(5):1672–80.

    Article  CAS  PubMed  Google Scholar 

  46. Zerr P, Palumbo-Zerr K, Distler A, Tomcik M, Vollath S, Munoz LE, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood. 2012;120(14):2909–17.

    Article  CAS  PubMed  Google Scholar 

  47. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104(5):1565–73.

    Article  CAS  PubMed  Google Scholar 

  48. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105(5):2227–34.

    Article  CAS  PubMed  Google Scholar 

  49. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.

    Article  CAS  PubMed  Google Scholar 

  50. Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, et al. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Ann Rheum Dis. 2015;74(6):1317–24.

    Google Scholar 

  51. Beyer C, Reichert H, Akan H, Mallano T, Schramm A, Dees C, et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis. 2013;72(7):1255–8.

    Article  CAS  PubMed  Google Scholar 

  52. Dees C, Zerr P, Tomcik M, Beyer C, Horn A, Akhmetshina A, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 2011;63(5):1396–404.

    Article  CAS  PubMed  Google Scholar 

  53. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis. 2011;70(7):1320–6.

    Article  CAS  PubMed  Google Scholar 

  54. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007;117(12):3786–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  56. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14(1):45–54.

    Article  CAS  PubMed  Google Scholar 

  57. Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M, et al. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis. 2013;72(6):1089–98.

    Article  CAS  PubMed  Google Scholar 

  58. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol. 2009;182(9):5855–64.

    Article  CAS  PubMed  Google Scholar 

  59. Kavian N, Servettaz A, Mongaret C, Wang A, Nicco C, Chereau C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010;62(11):3477–87.

    Article  CAS  PubMed  Google Scholar 

  60. Maurer B, Busch N, Jungel A, Pileckyte M, Gay RE, Michel BA, et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation. 2009;120(23):2367–76.

    Article  CAS  PubMed  Google Scholar 

  61. Maurer B, Distler JH, Distler O. The Fra-2 transgenic mouse model of systemic sclerosis. Vascul Pharmacol. 2013;58(3):194–201.

    Article  CAS  PubMed  Google Scholar 

  62. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010;62(1):280–90.

    Article  CAS  PubMed  Google Scholar 

  63. Manetti M, Rosa I, Milia AF, Guiducci S, Carmeliet P, Ibba-Manneschi L, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis. 2014;73(9):1700–9.

    Article  PubMed  Google Scholar 

  64. Mitchell RN. Graft vascular disease: immune response meets the vessel wall. Annu Rev Pathol. 2009;4:19–47.

    Article  CAS  PubMed  Google Scholar 

  65. Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res. 2007;100(7):967–78.

    Article  CAS  PubMed  Google Scholar 

  66. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest. 1997;100(3):550–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Dong C, Zhu S, Wang T, Yoon W, Goldschmidt-Clermont PJ. Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant. 2002;21(9):999–1008.

    Article  Google Scholar 

  68. Wick G, Andersson L, Hala K, Gershwin ME, Selmi C, Erf GF, et al. Avian models with spontaneous autoimmune diseases. Adv Immunol. 2006;92:71–117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Gruschwitz MS, Moormann S, Kromer G, Sgonc R, Dietrich H, Boeck G, et al. Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun. 1991;4(4):577–93.

    Article  CAS  PubMed  Google Scholar 

  70. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98(3):785–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Asano Y, Sato S. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep. 2013;15(12):382.

    Article  PubMed  Google Scholar 

  72. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163(2):571–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54(7):2271–9.

    Article  CAS  PubMed  Google Scholar 

  74. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176(4):1983–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, et al. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol (Hoboken, NJ). 2015;67(2):517–26.

    Article  CAS  Google Scholar 

  76. Noda S, Asano Y, Nishimura S, Taniguchi T, Fujiu K, Manabe I, et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun. 2014;5:5797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Dong JT, Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cellul Mol Life Sci: CMLS. 2009;66(16):2691–706.

    Article  CAS  Google Scholar 

  78. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A. 2003;100(21):12319–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest. 2010;120(1):254–65.

    Article  CAS  PubMed  Google Scholar 

  80. Fujiu K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest. 2011;121(9):3425–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol. 2004;41(12):1123–33.

    Article  CAS  PubMed  Google Scholar 

  82. Feghali-Bostwick C, Medsger Jr TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48(7):1956–63.

    Article  PubMed  Google Scholar 

  83. Sharif R, Mayes MD, Tan FK, Gorlova OY, Hummers LK, Shah AA, et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis. 2012;71(7):1197–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine. 2002;81(2):139–53.

    Article  PubMed  Google Scholar 

  85. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger Jr TA, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118(1):2–10.

    Article  PubMed  Google Scholar 

  86. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–44.

    Article  CAS  PubMed  Google Scholar 

  87. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139–53.

    Article  Google Scholar 

  88. Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol. 2010;28(5 Suppl 62):S48–53.

    CAS  PubMed  Google Scholar 

  89. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009;68(12):1878–84.

    Article  PubMed  Google Scholar 

  90. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation. 1976;53(3):483–90.

    Article  CAS  PubMed  Google Scholar 

  91. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum. 2007;56(11):3827–36.

    Article  PubMed  Google Scholar 

  92. Venalis P, Kumanovics G, Schulze-Koops H, Distler A, Dees C, Zerr P, et al. Cardiomyopathy in murine models of systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ). 2015;67(2):508–16.

    Article  CAS  Google Scholar 

  93. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A. 2002;99(17):11375–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Wunderlich C, Schober K, Lange SA, Drab M, Braun-Dullaeus RC, Kasper M, et al. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun. 2006;340(2):702–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Yoshihide Asano MD, PhD

  2. Department of Internal Medicine, University of Erlangen-Nuremberg, Erlangen-Nuremberg, Germany

    Jörg H. W. Distler MD

Authors
  1. Yoshihide Asano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg H. W. Distler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihide Asano MD, PhD .

Editor information

Editors and Affiliations

  1. Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

    John Varga

  2. Division of Medicine, Department of Inflammation, Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, Royal Free Hospital, London, United Kingdom

    Christopher P. Denton

  3. Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA

    Fredrick M. Wigley

  4. Service de Rhumatologie A, INSERMU1016, Universit. Paris Descartes, Hôpital Cochin, Paris, France

    Yannick Allanore

  5. Department of Allergy and Rheumatology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan

    Masataka Kuwana

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this chapter

Cite this chapter

Asano, Y., Distler, J.H.W. (2017). Overview of Animal Models. In: Varga, J., Denton, C., Wigley, F., Allanore, Y., Kuwana, M. (eds) Scleroderma. Springer, Cham. https://doi.org/10.1007/978-3-319-31407-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31407-5_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31405-1

  • Online ISBN: 978-3-319-31407-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation